XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.3
Stockholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Schedule of Reserved Shares of Common Stock for Future Issuance
As of September 30, 2025 and December 31, 2024, the Company had reserved shares of common stock for future issuance, on an as converted basis, as follows:
September 30, 2025December 31, 2024
Convertible preferred stock— 245,999 
RSUs (including CEO Equity Awards) outstanding90,531 73,951 
Stock options outstanding21,289 24,023 
Common stock warrants — 261 
Remaining shares authorized for future issuance74,162 2,864 
Total
185,982 347,098 
Schedule of Fair Value of Stock Options Granted The following table summarizes the assumptions used in estimating the fair value of the rights to acquire stock under the ESPP using the Black-Scholes option-pricing model:
Three Months Ended
September 30, 2025
Expected term0.3 years
Expected volatility42.49 %
Risk free interest rate4.30 %
Dividend yield — %
The following table summarizes the assumptions used in the valuation of the 2024 Stock Option Grants to employees during the three months ended September 30, 2024.
Three Months Ended
September 30, 2024
Expected term2.5 years
Expected volatility54.61 %
Risk free interest rate3.87 %
Dividend yield — %
Fair value of common stock on grant date$23.19 
Schedule of Incremental Stock-Based Compensation Expense
A summary of stock-based compensation expense recognized in the condensed consolidated statement of operations related to the May 2024 RSU Release and the incremental stock-based compensation expense from the 2024 Tender Offer is as follows, net of amounts capitalized as internal-use software:
Nine Months Ended
September 30, 2024
Cost of revenue$24,858 
Research and development462,683 
Sales and marketing186,659 
General and administrative183,618 
Total$857,818 
A summary of the related stock-based compensation expense recognized in the consolidated statement of operations related to the issuance of these stock option awards is as follows (in thousands), net of amounts capitalized as internal-use software:
Three Months Ended
September 30, 2024
Cost of revenue$3,034 
Research and development47,024 
Sales and marketing20,160 
General and administrative17,901 
Total$88,119 
Schedule of Stock Option Activity and Weighted-average Exercise Prices A summary of stock option activity and weighted-average exercise prices under the 2012 Plan and related information for the nine months ended September 30, 2025 is as follows:
Number of stock options outstanding under the 2012 PlanWeighted-average exercise price per shareWeighted-average remaining contractual term (in years)Aggregate intrinsic value
Outstanding as of December 31, 202424,023 $10.18 4.4$333,861 
Options exercised (2,734)17.40 — — 
Options forfeited — — — — 
Outstanding as of September 30, 202521,289 $9.25 2.4$907,323 
Vested and exercisable as of September 30, 202521,289 $9.25 2.4$907,323 
Schedule of Value of Options Exercised and Total Fair Value of Options
The following table summarizes information about the value of options exercised and total fair value of options vested during the three and nine months ended September 30, 2025 and 2024:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2025202420252024
Intrinsic value of options exercised$65,116 $100,670 $70,532 $106,164 
Schedule of Activity for Unvested RSUs The following table summarizes the activity for
the Company’s unvested RSUs under the 2012 Plan and the 2025 Plan during the nine months ended September 30, 2025, excluding the CEO equity awards described below:
Number of RSUs outstanding under the 2012 PlanWeighted-average grant date fair value per share
Unvested at December 31, 202454,826 $22.80 
RSUs granted 21,158 34.59 
RSUs released (20,918)19.91 
RSUs forfeited(4,745)25.81 
Total RSUs outstanding at September 30, 202550,321 28.67 
RSUs vested, not yet released at September 30, 2025(46)15.92 
Unvested at September 30, 202550,275 $28.68 
Schedule of Tranches Eligible to Vest Based on Achievement of Certain Public Market Capitalization Targets
The award is comprised of three tranches that are eligible to vest based on the achievement of certain public market capitalization targets as follows:
TranchePublic market capitalization targetsShares of Class B common stock vested (thousands)
1$15  billion1,875
2$20  billion3,750
3$25  billion5,625
11,250
The award is comprised of seven tranches that are eligible to vest based on the achievement of certain stock price targets as follows:
TrancheStock price targetsPercentage of shares of Class B common stock vested
1$60 per share15%
2$70 per share15%
3$80 per share15%
4$90 per share15%
5$100 per share14.5%
6$110 per share13.5%
7$130 per share12%
100%